deucravacitinib
bms
['lupus', 'deucra']
exciting work with 1117: efficacy and safety of deucravacitinib, an oral, selective, allosteric tyk2 inhibitor, in patients with active systemic lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study #acr22
Penn Medicine's Division of Rheumatology
National leader in diagnosis, treatment, and research in autoimmune diseases  @PennMedicineMD